Koss-Olinger Consulting’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-1,168
Closed -$254K – 173
2026
Q1
$254K Sell
1,168
-1,081
-48% -$240K 0.02% 235
2025
Q4
$514K Sell
2,249
-664
-23% -$151K 0.04% 166
2025
Q3
$541K Hold
2,913
– – 0.04% 189
2025
Q2
$541K Sell
2,913
-67
-2% -$12.5K 0.04% 191
2025
Q1
$624K Buy
+2,980
New +$579K 0.05% 158
2024
Q4
– Sell
-2,566
Closed -$507K – 186
2024
Q3
$507K Buy
2,566
+400
+18% +$74.7K 0.04% 159
2024
Q2
$371K Buy
+2,166
New +$359K 0.03% 183
2024
Q1
– Sell
-1,912
Closed -$296K – 47
2023
Q4
$296K Sell
1,912
-46
-2% -$6.71K 0.03% 239
2023
Q3
$292K Buy
1,958
+280
+17% +$41.1K 0.04% 194
2023
Q2
$226K Hold
1,678
– – 0.03% 234
2023
Q1
$267K Sell
1,678
-161
-9% -$24.6K 0.03% 188
2022
Q4
$297K Sell
1,839
-654
-26% -$100K 0.04% 161
2022
Q3
$335K Buy
2,493
+318
+15% +$45.6K 0.06% 133
2022
Q2
$333K Sell
2,175
-616
-22% -$94.1K 0.06% 120
2022
Q1
$452K Sell
2,791
-1,227
-31% -$178K 0.07% 108
2021
Q4
$544K Buy
4,018
+336
+9% +$39.7K 0.08% 98
2021
Q3
$397K Sell
3,682
-1,121
-23% -$128K 0.06% 141
2021
Q2
$541K Buy
4,803
+421
+10% +$47.4K 0.08% 126
2021
Q1
$474K Buy
+4,382
New +$469K 0.08% 132

Other funds holding ABBV

Koss-Olinger Consulting's ABBV Position: Q2 2026 in Review

Koss-Olinger Consulting sold out of AbbVie (ABBV) in Q2 2026, closing a stake of 1,168 shares — an estimated $254K sold.

Koss-Olinger Consulting first reported a position in ABBV in Q1 2021 and held it in 19 quarters. The position peaked at $624K in Q1 2025. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Koss-Olinger Consulting reported no remaining AbbVie position as of Q2 2026 after selling out during the quarter.
  • Koss-Olinger Consulting sold 1,168 AbbVie shares in Q2 2026, an estimated $254K.
  • Koss-Olinger Consulting first reported a position in AbbVie in Q1 2021 and held it in 19 quarters.
  • Koss-Olinger Consulting's AbbVie position peaked at $624K in Q1 2025.
  • 4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Koss-Olinger Consulting's 13F filing for Q2 2026, filed 10 Aug 2026.